---
document_datetime: 2023-09-21 20:57:10
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/vivanza-epar-procedural-steps-taken-authorisation_en.pdf
document_name: vivanza-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3921841
conversion_datetime: 2025-12-20 14:07:19.207596
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The company Bayer AG submitted on 10 April 2002 an application for Marketing Authorisation to the European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for  Vivanza,  through  the centralised  procedure.  After  agreement  by  the  CPMP  on  31  May  2001,  this  medicinal  product  has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

Rapporteur:

Gonzalo Calvo Rojas

Co-Rapporteur:

Barbara van Zwieten-Boot

Licensing status: The product was not licensed in any country at the time of submission of the application. 2. Steps taken for the assessment of the product · The procedure started on 22 April 2002 . · This  application  forms  part  of  a  multiple  application  together  with  Levitra  on  the  indication 'Treatment  of  erectile  dysfunction,  which  is  the  inability  to  achieve  or  maintain  a  penile reaction  sufficient  for  satisfactory  sexual  performance.'  Bayer  AG  submitted  the  initial application on 28 December 2001. · The  Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  Members  on  12  April 2002. The Co-Rapporteur's first assessment report was circulated to all CPMP Members on 10 April 2002. · During the meeting on 28-30 May 2002 the CPMP agreed on the consolidated list of questions to be sent to the company. The final consolidated list of questions was sent to the company on 31 May 2002. · The  company  submitted  the  responses  to  the  consolidated  list  of  questions  on  13  September 2002. · The Rapporteur or Co-Rapporteur circulated the response Assessment Report on the company's responses to the list of questions to all CPMP Members on 21 October 2002. · During  the  meeting  on  19-21  November  2002  the  CPMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for granting a Marketing Authorisation to Bayer AG on 21 November 2002. · The CPMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 4 March 2003. Medicinal product no longer authorised